Cancer drug prices: Experts seek use of compulsory licensing, tighter checks on pharma pricing

What happened

Public-health advocates say several costly cancer drugs saw no price cuts under the government's 30 per cent trade-margin cap. They want the government to use Patents Act provisions, including compulsory licences, which mean allowing others to make a patented medicine, to improve access.

Confirmed

Global impact / market context

The cap is meant to lower medicine bills, but it has worked unevenly. Generic and biosimilar brands cut prices, while some originator drugs barely moved. Compulsory licensing could force lower prices on those patented drugs, but it may also reduce the pricing power and revenue outlook for companies selling them.

Analyst inference

Investors in drug makers should separate companies benefiting from cheaper generics, like Cipla, from firms relying on high-priced patented cancer medicines. If compulsory licensing is used, sales and profit per sale on those products could fall, while public hospitals and patients may gain wider, cheaper access.

Analyst inference

What to watch

1. The article says AstraZeneca's anastrozole stayed at ₹3,541 while a competing Cipla brand fell sharply, showing the cap's uneven effect on cancer drug prices. Confirmed
2. Watch whether the government actually invokes Patents Act Sections 92 and 100, which the advocates proposed, because that decision would directly change pricing and supply rules for patented medicines. Proposed
3. Track which cancer drugs still show no price reduction under the margin cap, since those products are the most likely candidates for compulsory licensing or government use, affecting their makers' revenue. Analyst inference

Evidence

• Original source link unavailable